Clinical trial

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

NCT05296746

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Ribociclib (neoadjuvant) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Chemotherapy (adjuvant) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Ribociclib (adjuvant) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2022-05-03

PhasePHASE2

Conditions

Breast Cancer Stage IIunresolved

Interventions

Ribociclib (neoadjuvant)DRUG

Chemotherapy (adjuvant)DRUG

Ribociclib (adjuvant)DRUG

Sponsors & collaborators

SOLTI Breast Cancer Research Grouplead sponsor

Novartiscollaborator

UNICANCERcollaborator

Mapped research locations

MadridSpain4 BarcelonaSpain2 ValenciaSpain2 ToulouseFrance2 LyonFrance2 StrasbourgFrance2 LisbonPortugal2 ParisFrance1 SevilleSpain1 MarseilleFrance1 LilleFrance1 NantesFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05296746 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.